<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34684216</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-0817</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Pathogens (Basel, Switzerland)</Title><ISOAbbreviation>Pathogens</ISOAbbreviation></Journal><ArticleTitle>Uncertainty around the Long-Term Implications of COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1267</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pathogens10101267</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 231 million people globally, with more than 4.7 million deaths recorded by the World Health Organization as of 26 September 2021. In response to the pandemic, some countries (New Zealand, Vietnam, Taiwan, South Korea and others) have pursued suppression strategies, so-called Zero COVID policies, to drive and maintain infection rates as close to zero as possible and respond aggressively to new cases. In comparison, European countries and North America have adopted mitigation strategies (of varying intensity and effectiveness) that aim primarily to prevent health systems from being overwhelmed. With recent advances in our understanding of SARS-CoV-2 and its biology, and the increasing recognition there is more to COVID-19 beyond the acute infection, we offer a perspective on some of the long-term risks of mutational escape, viral persistence, reinfection, immune dysregulation and neurological and multi-system complications (Long COVID).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Desforges</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire Ste-Justine and Facult&#xe9; de M&#xe9;decine, D&#xe9;partement de Microbiologie, Infectiologie et Immunologie, Universit&#xe9; de Montr&#xe9;al, Montreal, QC H3T 1J4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gurdasani</LastName><ForeName>Deepti</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Queen Mary University of London, London E1 4NS, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamdy</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Panres Pandemic Research, Newport TF10 8PG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leonardi</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/S003711/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S003711/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pathogens</MedlineTA><NlmUniqueID>101596317</NlmUniqueID><ISSNLinking>2076-0817</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">neuroinvasion</Keyword><Keyword MajorTopicYN="N">post-acute COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">reinfection</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34684216</ArticleId><ArticleId IdType="pmc">PMC8536991</ArticleId><ArticleId IdType="doi">10.3390/pathogens10101267</ArticleId><ArticleId IdType="pii">pathogens10101267</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO  Weekly Epidemiological Update. Sep 28, 2021.  [(accessed on 30 September 2021)].  Available online:  https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---28-september-2021.</Citation></Reference><Reference><Citation>Patel J., Sridhar D. We should learn from the Asia&#x2013;Pacific responses to COVID-19. Lancet Reg. Heal. West. Pac. 2020;5:100062. doi: 10.1016/j.lanwpc.2020.100062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2020.100062</ArticleId><ArticleId IdType="pmc">PMC7694466</ArticleId><ArticleId IdType="pubmed">34173606</ArticleId></ArticleIdList></Reference><Reference><Citation>Priesemann V., Balling R., Brinkmann M.M., Ciesek S., Czypionka T., Eckerle I., Giordano G., Hanson C., Hel Z., Hotulainen P., et al. An action plan for pan-European defence against new SARS-CoV-2 variants. Lancet. 2021;397:469&#x2013;470. doi: 10.1016/S0140-6736(21)00150-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00150-1</ArticleId><ArticleId IdType="pmc">PMC7825950</ArticleId><ArticleId IdType="pubmed">33485462</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall M. The lasting misery of coronavirus long-haulers. Nature. 2020;585:339&#x2013;341. doi: 10.1038/d41586-020-02598-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-02598-6</ArticleId><ArticleId IdType="pubmed">32929257</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisblum Y., Schmidt F., Zhang F., DaSilva J., Poston D., Lorenzi J.C., Muecksch F., Rutkowska M., Hoffmann H.-H., Michailidis E., et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife. 2020;9 doi: 10.7554/eLife.61312.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.61312</ArticleId><ArticleId IdType="pmc">PMC7723407</ArticleId><ArticleId IdType="pubmed">33112236</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupont L., Snell L.B., Graham C., Seow J., Merrick B., Lechmere T., Hallett S.R., Charalampous T., Alcolea-Medina A., Huettner I., et al. Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections. medRxiv. 2021 doi: 10.1101/2021.06.07.21258351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.07.21258351</ArticleId></ArticleIdList></Reference><Reference><Citation>Carre&#xf1;o J.M., Alshammary H., Singh G., Raskin A., Amanat F., Amoako A., Gonzalez-Reiche A.S., van de Guchte A., Awawda M., Banu R., et al. Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37. medRxiv. 2021 doi: 10.1101/2021.07.21.21260961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.21.21260961</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Liu L., Iketani S., Luo Y., Guo Y., Wang M., Yu J., Zhang B., Kwong P.D., Graham B.S., et al. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. bioRxiv. 2021 doi: 10.1101/2021.01.25.428137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.25.428137</ArticleId><ArticleId IdType="pubmed">33684923</ArticleId></ArticleIdList></Reference><Reference><Citation>Buss L.F., Prete C.A., Jr., Abrahim C.M.M., Mendrone A., Jr., Salomon T., de Almeida-Neto C., Fran&#xe7;a R.F.O., Belotti M.C., Carvalho M.P.S.S., Costa A.G., et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon. during a largely unmitigated epidemic. Science. 2021;371:288&#x2013;292. doi: 10.1126/science.abe9728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe9728</ArticleId><ArticleId IdType="pmc">PMC7857406</ArticleId><ArticleId IdType="pubmed">33293339</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlcochova P., Kemp S., Dhar M.S., Papa G., Meng B., Mishra S., Whittaker C., Mellan T., Ferreira I., Datir R., et al. SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine break-through. Res. Sq. 2021 doi: 10.21203/rs.3.rs-637724/v1. preprint (Version 1)</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-637724/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J., Andrews N., Gower C., Gallagher E., Simmons R., Thelwall S., Stowe J., Tessier E., Groves N., Dabrera G., et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (delta) variant. N. Engl. J. Med. 2021;385:585&#x2013;594. doi: 10.1056/NEJMoa2108891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2108891</ArticleId><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>Eguia R.T., Crawford K.H.D., Stevens-Ayers T., Kelnhofer-Millevolte L., Greninger A.L., Englund J.A., Boeckh M.J., Bloom J.D. A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathog. 2021;17:e1009453. doi: 10.1371/journal.ppat.1009453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009453</ArticleId><ArticleId IdType="pmc">PMC8031418</ArticleId><ArticleId IdType="pubmed">33831132</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharun K., Tiwari R., Natesan S., Dhama K. SARS-CoV-2 infection in farmed minks, associated zoonotic concerns, and importance of the One Health approach during the ongoing COVID-19 pandemic. Vet. Q. 2021;41:50&#x2013;60. doi: 10.1080/01652176.2020.1867776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01652176.2020.1867776</ArticleId><ArticleId IdType="pmc">PMC7833041</ArticleId><ArticleId IdType="pubmed">33349165</ArticleId></ArticleIdList></Reference><Reference><Citation>Denison M., Graham R.L., Donaldson E.F., Eckerle L.D., Baric R.S. Coronaviruses. RNA Biol. 2011;8:270&#x2013;279. doi: 10.4161/rna.8.2.15013.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/rna.8.2.15013</ArticleId><ArticleId IdType="pmc">PMC3127101</ArticleId><ArticleId IdType="pubmed">21593585</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong S.W.X., Chiew C.J., Ang L.W., Mak T.-M., Cui L., Toh M.P.H.S., Lim Y.D., Lee P.H., Lee T.H., Chia P.Y., et al. Clinical and virological features of SARS-CoV-2 variants of concern: A retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta) Clin. Infect. Dis. 2021 doi: 10.1093/cid/ciab721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab721</ArticleId><ArticleId IdType="pmc">PMC8522361</ArticleId><ArticleId IdType="pubmed">34423834</ArticleId></ArticleIdList></Reference><Reference><Citation>Desforges M., Le Coupanec A., Dubeau P., Bourgouin A., Lajoie L., Dube M., Talbot P.J. Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? Viruses. 2019;12:14. doi: 10.3390/v12010014.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12010014</ArticleId><ArticleId IdType="pmc">PMC7020001</ArticleId><ArticleId IdType="pubmed">31861926</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Xiao J., Sun R., Tang X., Liang C., Lin H., Zeng L., Hu J., Yuan R., Zhou P., et al. Prolonged Persistence of SARS-CoV-2 RNA in Body Fluids. Emerg. Infect. Dis. 2020;26:1834&#x2013;1838. doi: 10.3201/eid2608.201097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2608.201097</ArticleId><ArticleId IdType="pmc">PMC7392422</ArticleId><ArticleId IdType="pubmed">32383638</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C., Wang Z., Lorenzi J., Muecksch F., Finkin S., Tokuyama M., Cho A., Jankovic M., Schaefer-Babajew D., Oliveira T.Y., et al. Evolution of antibody immunity to SARS-CoV-2. bioRxiv. 2021 doi: 10.1101/2020.11.03.367391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.11.03.367391</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussani R., Schneider E., Zentilin L., Collesi C., Ali H., Braga L., Volpe M.C., Colliva A., Zanconati F., Berlot G., et al. Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. EBioMedicine. 2020;61:103104. doi: 10.1016/j.ebiom.2020.103104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.103104</ArticleId><ArticleId IdType="pmc">PMC7677597</ArticleId><ArticleId IdType="pubmed">33158808</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J., Radke J., Dittmayer C., Franz J., Thomas C., Mothes R., Laue M., Schneider J., Br&#xfc;nink S., Greuel S., et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. 2021;24:168&#x2013;175. doi: 10.1038/s41593-020-00758-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00758-5</ArticleId><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke J., L&#xfc;tgehetmann M., Hagel C., Sperhake J.P., Schr&#xf6;der A.S., Edler C., Mushumba H., Fitzek A., Allweiss L., Dandri M., et al. Neuropathology of patients with COVID-19 in Germany: A post-mortem case series. Lancet Neurol. 2020;19:919&#x2013;929. doi: 10.1016/S1474-4422(20)30308-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30308-2</ArticleId><ArticleId IdType="pmc">PMC7535629</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Avanzato V.A., Matson M.J., Seifert S.N., Pryce R., Williamson B.N., Anzick S.L., Barbian K., Judson S.D., Fischer E.R., Martens C., et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell. 2020;183:1901&#x2013;1912.e9. doi: 10.1016/j.cell.2020.10.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.049</ArticleId><ArticleId IdType="pmc">PMC7640888</ArticleId><ArticleId IdType="pubmed">33248470</ArticleId></ArticleIdList></Reference><Reference><Citation>Vibholm L.K., Nielsen S.S.F., Pahus M.H., Frattari G.S., Olesen R., Andersen R., Monrad I., Andersen A.H.F., Thomsen M.M., Konrad C.V., et al. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine. 2021;64:103230. doi: 10.1016/j.ebiom.2021.103230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103230</ArticleId><ArticleId IdType="pmc">PMC7847186</ArticleId><ArticleId IdType="pubmed">33530000</ArticleId></ArticleIdList></Reference><Reference><Citation> [(accessed on 30 September 2021)].  Available online:  https://bnonews.com/index.php/2020/08/covid-19-reinfection-tracker/</Citation></Reference><Reference><Citation> [(accessed on 22 September 2021)].  Available online:  https://www.inspq.qc.ca/covid-19/vigie-reinfections.</Citation></Reference><Reference><Citation>Weekly National Influenza and COVID-19 Surveillance Report, Week 32 Report.  [(accessed on 22 September 2021)];2021 August 12; Available online:  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1010475/Weekly_Flu_and_COVID-19_report_w32.pdf.</Citation></Reference><Reference><Citation>Vabret A., Dina J., Brison E., Brouard J., Freymuth F. Coronavirus humains (HCoV) Pathol. Biol. 2009;57:149&#x2013;160. doi: 10.1016/j.patbio.2008.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.patbio.2008.02.018</ArticleId><ArticleId IdType="pmc">PMC7125620</ArticleId><ArticleId IdType="pubmed">18456429</ArticleId></ArticleIdList></Reference><Reference><Citation>Galanti M., Shaman J. Direct Observation of Repeated Infections with Endemic Coronaviruses. J. Infect. Dis. 2021;223:409&#x2013;415. doi: 10.1093/infdis/jiaa392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa392</ArticleId><ArticleId IdType="pmc">PMC7454749</ArticleId><ArticleId IdType="pubmed">32692346</ArticleId></ArticleIdList></Reference><Reference><Citation>Parry J. COVID-19: Hong Kong scientists report first confirmed case of reinfection. BMJ. 2020;370:m3340. doi: 10.1136/bmj.m3340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3340</ArticleId><ArticleId IdType="pubmed">32847834</ArticleId></ArticleIdList></Reference><Reference><Citation>Tillett R.L., Sevinsky J.R., Hartley P.D., Kerwin H., Crawford N., Gorzalski A., Laverdure C., Verma S.C., Rossetto C.C., Jackson D., et al. Genomic evidence for reinfection with SARS-CoV-2: A case study. Lancet Infect. Dis. 2021;21:52&#x2013;58. doi: 10.1016/S1473-3099(20)30764-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30764-7</ArticleId><ArticleId IdType="pmc">PMC7550103</ArticleId><ArticleId IdType="pubmed">33058797</ArticleId></ArticleIdList></Reference><Reference><Citation>What to Know About Breakthrough Infections and the Delta Variant.  [(accessed on 22 September 2021)].  Available online:  https://www.nytimes.com/article/covid-breakthrough-delta-variant.html.</Citation></Reference><Reference><Citation>Shastri J., Parikh S., Aggarwal V., Agrawal S., Chatterjee N., Shah R., Devi P., Mehta P., Pandey R. Severe SARS-CoV-2 Breakthrough Reinfection with Delta Variant After Recovery From Breakthrough Infection by Alpha Variant in a Fully Vaccinated Health Worker. Front. Med. 2021;8 doi: 10.3389/fmed.2021.737007.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.737007</ArticleId><ArticleId IdType="pmc">PMC8418387</ArticleId><ArticleId IdType="pubmed">34490316</ArticleId></ArticleIdList></Reference><Reference><Citation>Slezak J., Bruxvoort K., Fischer H., Broder B., Ackerson B., Tartof S. Rate and severity of suspected SARS-CoV-2 reinfection in a cohort of PCR-positive COVID-19 patients. Clin. Microbiol. Infect. 2021 doi: 10.1016/j.cmi.2021.07.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.07.030</ArticleId><ArticleId IdType="pmc">PMC8373524</ArticleId><ArticleId IdType="pubmed">34419576</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V.J., Foulkes S., Charlett A., Atti A., Monk E.J., Simmons R., Wellington E., Cole M., Saei A., Oguti B. Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020. Medrxiv. 2021 doi: 10.1101/2021.01.13.21249642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.13.21249642</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalfaoglu B., Almeida-Santos J., Tye C.A., Satou Y., Ono M. T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis. Front. Immunol. 2020;11:589380. doi: 10.3389/fimmu.2020.589380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.589380</ArticleId><ArticleId IdType="pmc">PMC7596772</ArticleId><ArticleId IdType="pubmed">33178221</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M., Gao Y., Wang G., Song G., Liu S., Sun D., Xu Y., Tian Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell. Mol. Immunol. 2020;17:533&#x2013;535. doi: 10.1038/s41423-020-0402-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0402-2</ArticleId><ArticleId IdType="pmc">PMC7091858</ArticleId><ArticleId IdType="pubmed">32203188</ArticleId></ArticleIdList></Reference><Reference><Citation>De Biasi S., Meschiari M., Gibellini L., Bellinazzi C., Borella R., Fidanza L., Gozzi L., Iannone A., Tartaro D.L., Mattioli M., et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat. Commun. 2020;11:1&#x2013;17. doi: 10.1038/s41467-020-17292-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17292-4</ArticleId><ArticleId IdType="pmc">PMC7338513</ArticleId><ArticleId IdType="pubmed">32632085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng M.H., Zhang S., Porritt R.A., Rivas M.N., Paschold L., Willscher E., Binder M., Arditi M., Bahar I. Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proc. Natl. Acad. Sci. USA. 2020;117:25254&#x2013;25262. doi: 10.1073/pnas.2010722117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2010722117</ArticleId><ArticleId IdType="pmc">PMC7568239</ArticleId><ArticleId IdType="pubmed">32989130</ArticleId></ArticleIdList></Reference><Reference><Citation>Park M.D. Immune evasion via SARS-CoV-2 ORF8 protein? Nat. Rev. Immunol. 2020;20:408. doi: 10.1038/s41577-020-0360-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0360-z</ArticleId><ArticleId IdType="pmc">PMC7273379</ArticleId><ArticleId IdType="pubmed">32504060</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Zhang J., Chen Y., Luo B., Yuan Y., Huang F., Yang T., Yu F., Liu J., Liu B., et al. The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Potently Downregulating MHC-I. bioRxiv. 2020 doi: 10.1101/2020.05.24.111823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.24.111823</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T., Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J., et al. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science. 2020:1249&#x2013;1255. doi: 10.1126/science.abc8665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc8665</ArticleId><ArticleId IdType="pmc">PMC7402621</ArticleId><ArticleId IdType="pubmed">32680882</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhaddou M., Memon D., Meyer B., White K.M., Rezelj V.V., Marrero M.C., Polacco B.J., Melnyk J.E., Ulferts S., Kaake R.M., et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell. 2020;182:685&#x2013;712.e19. doi: 10.1016/j.cell.2020.06.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.034</ArticleId><ArticleId IdType="pmc">PMC7321036</ArticleId><ArticleId IdType="pubmed">32645325</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontelli M.C., Castro I.A., Martins R.B., Veras F.P., La Serra L., Nascimento D.C., Cardoso R.S., Rosales R., Lima T.M., Souza J.P., et al. Infection of human lymphomononuclear cells by SARS-CoV-2. bioRxiv. 2020 doi: 10.1101/2020.07.28.225912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.28.225912</ArticleId></ArticleIdList></Reference><Reference><Citation>Davanzo G.G., Codo A.C., Brunetti N.S., Boldrini V.O., Knittel T.L., Monterio L.B., de Moraes D., Ferrari A.J.R., de Souza G.F., Muraro S.P., et al. SARS-CoV-2 Uses CD4 to Infect T Helper Lymphocytes. medRxiv. 2020 doi: 10.1101/2020.09.25.20200329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.25.20200329</ArticleId><ArticleId IdType="pmc">PMC10390044</ArticleId><ArticleId IdType="pubmed">37523305</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro A., Carter H., Zanetti M. Potential global impact of the N501Y mutation on MHC-II presentation and immune escape. bioRxiv. 2021 doi: 10.1101/2021.02.02.429431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.02.429431</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.-J., Ni Z.-Y., Hu Y., Liang W.-H., Ou C.-Q., He J.-X., Liu L., Shan H., Lei C.-L., Hui D.S., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708&#x2013;1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu P., Zhou Q., Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann. Hematol. 2020;99:1205&#x2013;1208. doi: 10.1007/s00277-020-04019-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-020-04019-0</ArticleId><ArticleId IdType="pmc">PMC7156897</ArticleId><ArticleId IdType="pubmed">32296910</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropa J., Cooper S., Capitano M.L., Hof W.V., Broxmeyer H.E. Human Hematopoietic Stem, Progenitor, and Immune Cells Respond Ex Vivo to SARS-CoV-2 Spike Protein. Stem Cell Rev. Rep. 2021;17:253&#x2013;265. doi: 10.1007/s12015-020-10056-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-020-10056-z</ArticleId><ArticleId IdType="pmc">PMC7577648</ArticleId><ArticleId IdType="pubmed">33089452</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Wherry E.J. T cell responses in patients with COVID-19. Nat. Rev. Immunol. 2020;20:529&#x2013;536. doi: 10.1038/s41577-020-0402-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0402-6</ArticleId><ArticleId IdType="pmc">PMC7389156</ArticleId><ArticleId IdType="pubmed">32728222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kratzer B., Trapin D., Ettel P., K&#xf6;rm&#xf6;czi U., Rottal A., Tuppy F., Feichter M., Gattinger P., Borochova K., Dorofeeva Y., et al. Immunological imprint of COVID-19 on human peripheral blood leukocyte populations. Allergy. 2021;76:751&#x2013;765. doi: 10.1111/all.14647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14647</ArticleId><ArticleId IdType="pmc">PMC7984452</ArticleId><ArticleId IdType="pubmed">33128792</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusnadi A., Ram&#xed;rez-Su&#xe1;stegui C., Fajardo V., Chee S.J., Meckiff B.J., Simon H., Pelosi E., Seumois G., Ay F., Vijayanand P., et al. Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8+ T cells. Sci. Immunol. 2021;6:eabe4782. doi: 10.1126/sciimmunol.abe4782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abe4782</ArticleId><ArticleId IdType="pmc">PMC8101257</ArticleId><ArticleId IdType="pubmed">33478949</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff M.C., Ramonell R.P., Saini A.S., Haddad N.S., Anam F.A., Rudolph M.E., Bugrovsky R., Hom J., Cashman K.S., Nguyen D.C., et al. Clinically identifiable autoreactivity is common in severe SARS-CoV-2 Infection. medRxiv. 2020 doi: 10.1101/2020.10.21.20216192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.21.20216192</ArticleId></ArticleIdList></Reference><Reference><Citation>Talotta R., Robertson E. Autoimmunity as the comet tail of COVID-19 pandemic. World J. Clin. Cases. 2020;8:3621&#x2013;3644. doi: 10.12998/wjcc.v8.i17.3621.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v8.i17.3621</ArticleId><ArticleId IdType="pmc">PMC7479552</ArticleId><ArticleId IdType="pubmed">32953841</ArticleId></ArticleIdList></Reference><Reference><Citation>Agerer B., Koblischke M., Gudipati V., Smyth M., Popa A., Genger J., Endler L., Florian D.M., M&#xfc;hlgrabner V., Lercher A., et al. SARS-CoV-2 escapes CD8 T cell surveillance via mutations in MHC-I restricted epitopes. bioRxiv. 2020 doi: 10.1101/2020.12.18.423507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.18.423507</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretti M.A.M., Galvani R.G., Farias A.S., Boroni M. New SARS-CoV-2 lineages could evade CD8+ T-cells response. bioRxiv. 2021 doi: 10.1101/2021.03.09.434584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.09.434584</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuniga M., Gomes C., Carsons S.E., Bender M.T., Cotzia P., Miao Q.R., Lee D.C., Rodriguez A. Autoimmunity to Annexin A2 predicts mortality among hospitalised COVID-19 patients. Eur. Respir. J. 2021:2100918. doi: 10.1183/13993003.00918-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00918-2021</ArticleId><ArticleId IdType="pmc">PMC8859972</ArticleId><ArticleId IdType="pubmed">34244321</ArticleId></ArticleIdList></Reference><Reference><Citation>Murugan A.K., Alzahrani A.S. SARS-CoV-2 plays a pivotal role in inducing hyperthyroidism of Graves&#x2019; disease. Endocrine. 2021;73:243&#x2013;254. doi: 10.1007/s12020-021-02770-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-021-02770-6</ArticleId><ArticleId IdType="pmc">PMC8188762</ArticleId><ArticleId IdType="pubmed">34106438</ArticleId></ArticleIdList></Reference><Reference><Citation>British Society for Immunology . Long-Term Immunological Health Consequences of COVID-19. British Society for Immunology; London, UK: 2020.</Citation></Reference><Reference><Citation>Nabavi N. Long COVID: How to define it and how to manage it. BMJ. 2020;370:m3489. doi: 10.1136/bmj.m3489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3489</ArticleId><ArticleId IdType="pubmed">32895219</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics . Updated Estimates of the Prevalence of Long COVID Symptoms. Office for National Statistics; Newport, UK: 2021.</Citation></Reference><Reference><Citation>Office for National Statistics . Coronavirus (COVID-19) latest insights: Infections, 28 September 2021. Office for National Statistics; Newport, UK: 2021.</Citation></Reference><Reference><Citation>Whitaker M., Elliott J., Chadeau-Hyam M., Riley S., Darzi A., Cooke G., Ward H., Elliott P.  Persistent Symptoms Following SARS-CoV-2 Infection in a Random Community Sample of 508,707 People. Imperial College London; London, UK: 2021.  [(accessed on 20 September 2021)].  Available online:  http://hdl.handle.net/10044/1/89844.</Citation></Reference><Reference><Citation>Office for National Statistics . Prevalence of Ongoing Symptoms following Coronavirus (COVID-19) Infection in the UK: 2 September 2021. Office for National Statistics; Newport, UK: 2021.</Citation></Reference><Reference><Citation>Deinhardt-Emmer S., Wittschieber D., Sanft J., Kleemann S., Elschner S., Haupt K.F., Vau V., H&#xe4;ring C., R&#xf6;del J., Henke A., et al. Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and correlation to tissue damage. bioRxiv. 2020 doi: 10.1101/2020.07.01.182550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.01.182550</ArticleId><ArticleId IdType="pmc">PMC8009677</ArticleId><ArticleId IdType="pubmed">33781385</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill J.T., Erkan D., Winakur J., James J.A. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat. Rev. Rheumatol. 2020;16:581&#x2013;589. doi: 10.1038/s41584-020-0474-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0474-5</ArticleId><ArticleId IdType="pmc">PMC7391481</ArticleId><ArticleId IdType="pubmed">32733003</ArticleId></ArticleIdList></Reference><Reference><Citation>Bose R.J., McCarthy J.R. Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19. Drug Discov. Today. 2020;25:1559&#x2013;1560. doi: 10.1016/j.drudis.2020.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2020.06.021</ArticleId><ArticleId IdType="pmc">PMC7313487</ArticleId><ArticleId IdType="pubmed">32592868</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P., Nath A., Beckham J.D. Is COVID-19 a Perfect Storm for Parkinson&#x2019;s Disease? Trends Neurosci. 2020;43:931&#x2013;933. doi: 10.1016/j.tins.2020.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.10.009</ArticleId><ArticleId IdType="pmc">PMC7577682</ArticleId><ArticleId IdType="pubmed">33158605</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath A., Smith B. Neurological complications of COVID-19: From bridesmaid to bride. Arq. Neuro-Psiquiatria. 2020;78:459&#x2013;460. doi: 10.1590/0004-282x20200121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0004-282x20200121</ArticleId><ArticleId IdType="pubmed">32901698</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig A.M. Neurological manifestations in COVID-19 caused by SARS-CoV-2. CNS Neurosci. Ther. 2020;26:499&#x2013;501. doi: 10.1111/cns.13372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.13372</ArticleId><ArticleId IdType="pmc">PMC7163592</ArticleId><ArticleId IdType="pubmed">32266761</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall M. How COVID-19 can damage the brain. Nature. 2020;585:342&#x2013;343. doi: 10.1038/d41586-020-02599-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-02599-5</ArticleId><ArticleId IdType="pubmed">32934351</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano G.E., Walker J.E., Arce R., Glass M.J., Vargas D., Sue L.I., Intorcia A.J., Nelson C.M., Oliver J., Papa J., et al. Mapping of SARS-CoV-2 Brain Invasion and Histopathology in COVID-19 Disease. medRxiv. 2021 doi: 10.1101/2021.02.15.21251511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.15.21251511</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E., Zhang C., Israelow B., Lu-Culligan A., Prado A.V., Skriabine S., Lu P., Weizman O.-E., Liu F., Dai Y., et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J. Exp. Med. 2021;218:e20202135. doi: 10.1084/jem.20202135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20202135</ArticleId><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="pubmed">33433624</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G., Lee S., Alfaro-Almagro F., Arthofer C., Wang C., Lange F., Andersson J.L.R., Griffanti L., Duff E., Jbabdi S., et al. Brain imaging before and after COVID-19 in UK Biobank. medRxiv. 2021 doi: 10.1101/2021.06.11.21258690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.11.21258690</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang A.C., Kern F., Losada P.M., Agam M.R., Maat C.A., Schmartz G.P., Fehlmann T., Stein J.A., Schaum N., Lee D.P., et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nat. Cell Biol. 2021;595:565&#x2013;571. doi: 10.1038/s41586-021-03710-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03710-0</ArticleId><ArticleId IdType="pmc">PMC8400927</ArticleId><ArticleId IdType="pubmed">34153974</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand A., Campion J.-Y., Lepine A., Bosdure E., Luciani L., Cammilleri S., Chabrol B., Guedj E. Similar patterns of [18F]-FDG brain PET hypometabolism in paediatric and adult patients with long COVID: A paediatric case series. Eur. J. Nucl. Med. Mol. Imaging. 2021:1&#x2013;8. doi: 10.1007/s00259-021-05528-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05528-4</ArticleId><ArticleId IdType="pmc">PMC8376118</ArticleId><ArticleId IdType="pubmed">34414470</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A., Trender W., Chamberlain S.R., Jolly A.E., Grant J.E., Patrick F., Mazibuko N., Williams S.C., Barnby J.M., Hellyer P., et al. Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine. 2021;39:101044. doi: 10.1016/j.eclinm.2021.101044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101044</ArticleId><ArticleId IdType="pmc">PMC8298139</ArticleId><ArticleId IdType="pubmed">34316551</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B., Mohn K.G.-I., Brokstad K.A., Zhou F., Linchausen D.W., Hansen B.-A., Lartey S., Onyango T.B., Kuwelker K., S&#xe6;vik M., et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 2021;27:1607&#x2013;1613. doi: 10.1038/s41591-021-01433-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginther D.K., Zambrana C. Association of Mask Mandates and COVID-19 Case Rates, Hospitalizations, and Deaths in Kansas. JAMA Netw. Open. 2021;4:e2114514. doi: 10.1001/jamanetworkopen.2021.14514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.14514</ArticleId><ArticleId IdType="pmc">PMC8223099</ArticleId><ArticleId IdType="pubmed">34160607</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Liang M., Gao L., Ahmed M.A., Uy J.P., Cheng C., Zhou Q., Sun C. Face masks to prevent transmission of COVID-19: A systematic review and meta-analysis. Am. J. Infect. Control. 2021;49:900&#x2013;906. doi: 10.1016/j.ajic.2020.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajic.2020.12.007</ArticleId><ArticleId IdType="pmc">PMC7748970</ArticleId><ArticleId IdType="pubmed">33347937</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsley W.G., Blachere F.M., Law B.F., Beezhold D.H., Noti J.D. Efficacy of face masks, neck gaiters and face shields for reducing the expulsion of simulated cough-generated aerosols. Aerosol Sci. Technol. 2021;55:449&#x2013;457. doi: 10.1080/02786826.2020.1862409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02786826.2020.1862409</ArticleId><ArticleId IdType="pmc">PMC9345365</ArticleId><ArticleId IdType="pubmed">35924077</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris M., Ferris R., Workman C., O&#x2019;Connor E., Enoch D.A., Goldesgeyme E., Quinnell N., Patel P., Wright J., Martell G., et al. FFP3 respirators protect healthcare workers against infection with SARS-CoV-2. Authorea. 2021 doi: 10.22541/au.162454911.17263721/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.22541/au.162454911.17263721/v1</ArticleId><ArticleId IdType="pmc">PMC8635983</ArticleId><ArticleId IdType="pubmed">34783656</ArticleId></ArticleIdList></Reference><Reference><Citation>Gettings J., Czarnik M., Morris E., Haller E., Thompson-Paul A.M., Rasberry C., Lanzieri T.M., Smith-Grant J., Aholou T.M., Thomas E., et al. Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools&#x2014;Georgia, November 16&#x2013;December 11, 2020. MMWR. Morb. Mortal. Wkly. Rep. 2021;70:779&#x2013;784. doi: 10.15585/mmwr.mm7021e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7021e1</ArticleId><ArticleId IdType="pmc">PMC8158891</ArticleId><ArticleId IdType="pubmed">34043610</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry G., Parsons A., Morgan M., Rickert J., Cho H. A review of methods to reduce the probability of the airborne spread of COVID-19 in ventilation systems and enclosed spaces. Environ. Res. 2022;203:111765. doi: 10.1016/j.envres.2021.111765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2021.111765</ArticleId><ArticleId IdType="pmc">PMC8317458</ArticleId><ArticleId IdType="pubmed">34331921</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>